Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer

NCT03734809 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT03734809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03734809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 3, 2019
Completion date
December 31, 2027
Enrollment
43 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

npc